Stephanie Monaghan O’brien
directors
bioinformatics and system biology
Aduro Biotech
Netherlands
Biography
Stephanie Monaghan O’Brien has served as a member of our board of directors since 2011. Ms. O’Brien has been a member of the investment team at Morningside since 1997. She has served as a director for numerous private nonclinical and clinical stage companies developing drugs across a broad spectrum of therapeutic focus, including oncology and immunotherapy, and has extensive experience providing operational and management oversight to venture-backed technology companies.
Research Interest
Current Synthetic and Systems Biology
